Metabolic links between diabetes and Alzheimer’s disease

References

• Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol.61(5), 661–666 (2004).
   PubMed Web of Science ®Google Scholar
• Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systemic review. Lancet Neurol.5, 64–74 (2006).
   PubMed Web of Science ®Google Scholar
• Cali AM, Caprio S. Prediabetes and Type 2 diabetes in youth: an emerging epidemic disease? Curr. Opin. Endocrinol. Diabetes Obes15(2), 123–127 (2008).
   PubMed Web of Science ®Google Scholar
• Craft S. Insulin resistance and Alzheimer’s disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer Res4(2), 147–152 (2007).
   PubMed Web of Science ®Google Scholar
• Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology53, 1937–1942 (1999).
   PubMed Web of Science ®Google Scholar
• Katzman R, Aronson M, Fuld P et al. Development of dementing illnesses in an 80-year-old volunteer cohort. Ann. Neurol.25, 317–324 (1989).
   PubMed Web of Science ®Google Scholar
• Hassing LB, Johansson B, Nilsson SE et al. Diabetes mellitus is a risk factor for vascular dementia, but not Alzheimer’s disease: a population-based study of the oldest old. Int. Psychogeriatr.14, 239–248 (2002).
   PubMed Web of Science ®Google Scholar
• Bruce DG, Davis WA, Casey GP et al. Predictors of cognitive impairment and dementia in older people with diabetes. Diabetologia51, 241–248 (2008).
   PubMed Web of Science ®Google Scholar
• Akomolafe A, Beiser A, Meigs JB et al. Diabetes mellitus and risk of developing Alzheimer disease. Arch. Neurol.63, 1551–1555 (2006).
   PubMed Web of Science ®Google Scholar
• Xu W, Qiu C, Winblad B, Fratriglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer’s disease. Diabetes56, 211–216 (2007).
   PubMed Web of Science ®Google Scholar
• Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies. Diabetes51, 1256–1262 (2002).
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Tang M-X, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology63, 1187–1192 (2004).
   PubMed Web of Science ®Google Scholar
• Young SE, Mainous AG, Carnemolla M. Hyperinsulinemia and cognitive decline in a middle-aged cohort. Diabetes Care29, 2688–2693 (2006).
   PubMed Web of Science ®Google Scholar
• Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology63, 658–663 (2004).
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Tang M-X, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am. J. Epidemiol.154, 635–641 (2001).
   PubMed Web of Science ®Google Scholar
• Xu W, Qiu CX, Wahlin A, Winblad B, Fratriglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project. Neurology63, 1181–1186 (2004).
   PubMed Web of Science ®Google Scholar
• Ronnemaa E, Zethelius B, Sundelof J et al. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology71, 1065–1071 (2008).
   PubMed Web of Science ®Google Scholar
• Youngren JF. Regulation of insulin receptor function. Cell. Mol. Life Sci.64, 873–891 (2007).
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet365, 1333–1346 (2005).
   PubMed Web of Science ®Google Scholar
• Cole AR, Astell A, Green C, Sutherland C. Molecular connections between dementia and diabetes. Neurosci. Biobehav. Rev.31, 1046–1063 (2007).
   PubMed Web of Science ®Google Scholar
• Neumann KF, Rojo L, Navarrete LP, Farias G, Reyes P, Maccioni RB. Insulin resistance and Alzheimer’s disease: molecular links & clinical implications. Curr. Alzheimer Res.5, 438–447 (2008).
   PubMed Web of Science ®Google Scholar
• Sweatt JD. Mitogen-activated protein kinases in synaptic plasticity and memory. Curr. Opin. Neurobiol.14, 311–317 (2004).
   PubMed Web of Science ®Google Scholar
• Tully T, Bourtchouladze R, Scott R, Tallman J. Targeting the CREB pathway for memory enhancers. Nat. Rev. Drug Discov.2, 267–277 (2003).
   PubMed Web of Science ®Google Scholar
• Carlezon WA, Duman RS, Nestler EJ. The many faces of CREB. Trends Neurosci.28, 436–445 (2005).
   PubMed Web of Science ®Google Scholar
• Horwood JM, Dufour F, Laroche S, Davis S. Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. Eur. J. Neurosci.23, 3375–3384 (2006).
   PubMed Web of Science ®Google Scholar
• Phiel CJ, Wilson CA, Lee VM-Y, Klein PS. GSK-3a regulates production of Alzheimer’s disease amyloid-peptides. Nature423, 435–439 (2003).
   PubMed Web of Science ®Google Scholar
• Alafuzoff I, Aho L, Helisalmi S, Mannermaa A, Soininen H. β-amyloid deposition in brains of subjects with diabetes. Neuropathol. Appl. Neurobiol.35(1), 60–68 (2009).
   PubMed Web of Science ®Google Scholar
• Arvanitakis Z, Schneider JA, Wilson RS et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology67(11), 1960–1965 (2006).
   PubMed Web of Science ®Google Scholar
• Harrington LS, Findlay GM, Lamb RF. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem. Sci.30, 35–42 (2005).
   PubMed Web of Science ®Google Scholar
• Higuchi M, Onishi K, Kikuchi C, Gotoh Y. Scaffolding function of PAK in the PDK1–Akt pathway. Nat. Cell Biol.10, 1356–1364 (2008).
   PubMed Web of Science ®Google Scholar
• Zhao L, Ma Q-L, Calon F et al. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat. Neurosci.9, 234–242 (2006).
   PubMed Web of Science ®Google Scholar
• Schubert M, Gautam D, Surjo D et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl Acad. Sci. USA101, 3100–3105 (2004).
   PubMed Web of Science ®Google Scholar
• Mielke JG, Taghibiglou C, Liu L et al. A biochemical and functional characterization of diet-induced brain insulin resistance. J. Neurochem.93, 1568–1578 (2005).
   PubMed Web of Science ®Google Scholar
• Stranahan AM, Norman ED, Lee K et al. Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus18, 1085–1088 (2008).
   PubMed Web of Science ®Google Scholar
• Ho L, Qin W, Pompl PN et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease. FASEB J.18, 902–904 (2004).
   PubMed Web of Science ®Google Scholar
• Farris W, Mansourian S, Chang Y et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc. Natl Acad. Sci. USA100, 4162–4167 (2003).
   PubMed Web of Science ®Google Scholar
• Burdo JR, Chen Q, Calcutt NA, Schubert D. The pathological interaction between diabetes and presymptomatic Alzheimer’s disease. Neurobiol. Aging (2008) (Epub ahead of print). doi:10.1016/j.neurobiolaging.2008.02.010
   PubMedGoogle Scholar
• Jenkins AJ, Best JD, Klein RL, Lyons TJ. ‘Lipoproteins, glycoxidation and diabetic angiopathy’. Diabetes Metab. Res. Rev.20(5), 349–368 (2004).
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet365(9468), 1415–1428 (2005).
   PubMed Web of Science ®Google Scholar
• Hillered L, Chan PH. Role of arachidonic acid and other free fatty acids in mitochondrial dysfunction in brain ischemia. J. Neurosci. Res.20(4), 451–456 (1988).
   PubMed Web of Science ®Google Scholar
• Hamel FG, Upward JL, Bennett RG. In vitro inhibition of insulin-degrading enzyme by long-chain fatty acids and their coenzyme A thioesters. Endocrinology144(6), 2404–2408 (2003).
   PubMed Web of Science ®Google Scholar
• Dahlen SE, Bjork J, Hedqvist P et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc. Natl Acad. Sci. USA78(6), 3887–3891 (1981).
   PubMed Web of Science ®Google Scholar
• Wilson DM, Binder LI. Free fatty acids stimulate the polymerization of tau and amyloid β peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer’s disease. Am. J. Pathol.150(6), 2181–2195 (1997).
   PubMed Web of Science ®Google Scholar
• Gamblin TC, King ME, Kuret J, Berry RW, Binder LI. Oxidative regulation of fatty acid-induced tau polymerization. Biochemistry39(46), 14203–14210 (2000).
   PubMed Web of Science ®Google Scholar
• Craft S. Insulin resistance syndrome and Alzheimer’s disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol. Aging26(Suppl. 1), 65–69 (2005).
   PubMed Web of Science ®Google Scholar
• Rapoport SI. Brain arachidonic and docosahexaenoic acid cascades are selectively altered by drugs, diet and disease. Prostaglandins Leukot. Essent. Fatty Acids79(3–5), 153–156 (2008).
   PubMed Web of Science ®Google Scholar
• Firuzi O, Zhuo J, Chinnici CM, Wisniewski T, Pratico D. 5-lipoxygenase gene disruption reduces amyloid-β pathology in a mouse model of Alzheimer’s disease. FASEB J.22(4), 1169–1178 (2008).
   PubMed Web of Science ®Google Scholar
• Sanchez-Mejia RO, Newman JW, Toh S et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer’s disease. Nat. Neurosci.11(11), 1311–1318 (2008).
   PubMed Web of Science ®Google Scholar
• Lim GP, Calon F, Morihara T et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci.25(12), 3032–3040 (2005).
   PubMed Web of Science ®Google Scholar
• Roland I, De Leval X, Evrard B, Pirotte B, Dogne JM, Delattre L. Modulation of the arachidonic cascade with omega3 fatty acids or analogues: potential therapeutic benefits. Mini Rev. Med. Chem.4(6), 659–668 (2004).
   PubMed Web of Science ®Google Scholar
• Williams JH, Errington ML, Lynch MA, Bliss TV. Arachidonic acid induces a long-term activity-dependent enhancement of synaptic transmission in the hippocampus. Nature341(6244), 739–742 (1989).
   Google Scholar
• Massicotte G. Modification of glutamate receptors by phospholipase A2: its role in adaptive neural plasticity. Cell. Mol. Life Sci.57(11), 1542–1550 (2000).
   PubMed Web of Science ®Google Scholar
• Scorrano L, Penzo D, Petronilli V, Pagano F, Bernardi P. Arachidonic acid causes cell death through the mitochondrial permeability transition. Implications for tumor necrosis factor-α aopototic signaling. J. Biol. Chem.276(15), 12035–12040 (2001).
   PubMed Web of Science ®Google Scholar
• Penzo D, Petronilli V, Angelin A et al. Arachidonic acid released by phospholipase A(2) activation triggers Ca2+-dependent apoptosis through the mitochondrial pathway. J. Biol. Chem.279(24), 25219–25225 (2004).
   PubMed Web of Science ®Google Scholar
• Tanaka E, Niiyama S, Sato S, Yamada A, Higashi H. Arachidonic acid metabolites contribute to the irreversible depolarization induced by in vitro ischemia. J. Neurophysiol.90(5), 3213–3223 (2003).
   PubMed Web of Science ®Google Scholar
• Cherny VV, Henderson LM, Xu W, Thomas LL, DeCoursey TE. Activation of NADPH oxidase-related proton and electron currents in human eosinophils by arachidonic acid. J. Physiol.535(Pt 3), 783–794 (2001).
   PubMed Web of Science ®Google Scholar
• Zhu D, Lai Y, Shelat PB, Hu C, Sun GY, Lee JC. Phospholipases A2 mediate amyloid-β peptide-induced mitochondrial dysfunction. J. Neurosci.26(43), 11111–11119 (2006).
   PubMed Web of Science ®Google Scholar
• Bianca VD, Dusi S, Bianchini E, Dal Pra I, Rossi F. β-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer’s disease. J. Biol. Chem.274(22), 15493–15499 (1999).
   PubMed Web of Science ®Google Scholar
• Schubert D, Soucek T, Blouw B. HIF-1 protects astrocytes from activation by amyloid β peptide. Eur. J. Neurosci.29, 1323–1334 (2009).
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer’s disease. Curr. Pharmaceut. Des.14(10), 973–978 (2008).
   PubMed Web of Science ®Google Scholar
• Sun GY, Horrocks LA, Farooqui AA. The roles of NADPH oxidase and phospholipases A2 in oxidative and inflammatory responses in neurodegenerative diseases. J. Neurochem.103(1), 1–16 (2007).
   PubMed Web of Science ®Google Scholar
• Sun GY, Xu J, Jensen MD, Simonyi A. Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J. Lipid Res.45(2), 205–213 (2004).
   PubMed Web of Science ®Google Scholar
• Uz T, Pesold C, Longone P, Manev H. Aging-associated up-regulation of neuronal 5-lipoxygenase expression: putative role in neuronal vulnerability. FASEB J.12(6), 439–449 (1998).
   PubMed Web of Science ®Google Scholar
• Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med.12(9), 1005–1015 (2006).
   PubMed Web of Science ®Google Scholar
• Tan S, Sagara Y, Liu Y, Maher P, Schubert D. The regulation of reactive oxygen species production during programmed cell death. J. Cell Biol.141(6), 1423–1432 (1998).
   PubMed Web of Science ®Google Scholar
• Mitchell DC, Gawrisch K, Litman BJ, Salem N Jr. Why is docosahexaenoic acid essential for nervous system function? Biochem. Soc. Trans.26(3), 365–370 (1998).
   PubMed Web of Science ®Google Scholar
• Soderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer’s disease. Lipids26(6), 421–425 (1991).
   PubMed Web of Science ®Google Scholar
• Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR. Regional membrane phospholipid alterations in Alzheimer’s disease. Neurochem. Res.23(1), 81–88 (1998).
   PubMed Web of Science ®Google Scholar
• Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann. Neurol.42(5), 776–782 (1997).
   PubMed Web of Science ®Google Scholar
• Hooijmans CR, Rutters F, Dederen PJ et al. Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched typical Western diet (TWD). Neurobiol. Dis.28(1), 16–29 (2007).
   PubMed Web of Science ®Google Scholar
• Wakil SJ, Abu-Elheiga LA. Fatty acid metabolism: target for metabolic syndrome. J. Lipid Res. (2008) (Epub ahead of print) doi:10.1194/jlr.R800079-JLR200.
   Google Scholar
• Parks EJ, Skokan LE, Timlin MT, Dingfelder CS. Dietary sugars stimulate fatty acid synthesis in adults. J. Nutr.138(6), 1039–1046 (2008).
   PubMed Web of Science ®Google Scholar
• Cumming RC, Dargusch R, Fischer WH, Schubert D. Increase in expression levels and resistance to sulfhydryl oxidation of peroxiredoxin isoforms in amyloid β-resistant nerve cells. J. Biol. Chem.282(42), 30523–30534 (2007).
   PubMed Web of Science ®Google Scholar
• Thornalley PJ. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification – a role in pathogenesis and antiproliferative chemotherapy. Gen. Pharmacol.27(4), 565–573 (1996).
   PubMedGoogle Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature414(6865), 813–820 (2001).
   PubMed Web of Science ®Google Scholar
• Kuhla B, Luth HJ, Haferburg D, Boeck K, Arendt T, Munch G. Methylglyoxal, glyoxal, and their detoxification in Alzheimer’s disease. Ann. NY Acad. Sci.1043, 211–216 (2005).
   PubMed Web of Science ®Google Scholar
• Chen F, Wollmer MA, Hoerndli F et al. Role for glyoxalase I in Alzheimer’s disease. Proc. Natl Acad. Sci. USA101(20), 7687–7692 (2004).
   PubMed Web of Science ®Google Scholar
• Fukunaga M, Miyata S, Higo S, Hamada Y, Ueyama S, Kasuga M. Methylglyoxal induces apoptosis through oxidative stress-mediated activation of p38 mitogen-activated protein kinase in rat Schwann cells. Ann. NY Acad. Sci.1043, 151–157 (2005).
   PubMed Web of Science ®Google Scholar
• Hipkiss AR. On the mechanisms of ageing suppression by dietary restriction-is persistent glycolysis the problem? Mec. Ageing Dev.127(1), 8–15 (2006).
   PubMed Web of Science ®Google Scholar
• Morcos M, Du X, Pfisterer F et al. Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell7(2), 260–269 (2008).
   PubMed Web of Science ®Google Scholar
• Schubert D. Glucose metabolism and Alzheimer’s disease. Ageing Res. Rev.4, 240–257 (2005).
   PubMed Web of Science ®Google Scholar
• Soucek T, Cumming R, Dargusch R, Maher P, Schubert D. The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid β peptide. Neuron39(1), 43–56 (2003).
   PubMed Web of Science ®Google Scholar
• Ishige K, Schubert D, Sagara Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic. Biol. Med.30, 433–446 (2001).
   PubMed Web of Science ®Google Scholar
• Thornalley PJ. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int. Rev. Neurobiol.50, 37–57 (2002).
   PubMed Web of Science ®Google Scholar
• Thurston JH, McDougal DB Jr, Hauhart RE, Schulz DW. Effects of acute, subacute, and chronic diabetes on carbohydrate and energy metabolism in rat sciatic nerve. Relation to mechanisms of peripheral neuropathy. Diabetes44(2), 190–195 (1995).
   PubMed Web of Science ®Google Scholar
• Williamson JR, Chang K, Frangos M et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes42(6), 801–813 (1993).
   PubMed Web of Science ®Google Scholar
• Munch G, Kuhla B, Luth HJ, Arendt T, Robinson SR. Anti-AGEing defences against Alzheimer’s disease. Biochem. Soc. Trans.31(Pt 6), 1397–1399 (2003).
   PubMed Web of Science ®Google Scholar
• Smith MA, Taneda S, Richey PL et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl Acad. Sci. USA91(12), 5710–5714 (1994).
   PubMed Web of Science ®Google Scholar
• Yan SD, Yan SF, Chen X et al. Non-enzymatically glycated tau in Alzheimer’s disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nat. Med.1(7), 693–699 (1995).
   PubMed Web of Science ®Google Scholar
• Choei H, Sasaki N, Takeuchi M et al. Glyceraldehyde-derived advanced glycation end products in Alzheimer’s disease. Acta Neuropathol.108(3), 189–193 (2004).
   PubMed Web of Science ®Google Scholar
• Li ZG, Zhang W, Sima AA. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes56(7), 1817–1824 (2007).
   PubMed Web of Science ®Google Scholar
• Vitek MP, Bhattacharya K, Glendening JM et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl Acad. Sci. USA91(11), 4766–4770 (1994).
   PubMed Web of Science ®Google Scholar
• Ledesma MD, Bonay P, Colaco C, Avila J. Analysis of microtubule-associated protein tau glycation in paired helical filaments. J. Biol. Chem.269(34), 21614–21619 (1994).
   PubMed Web of Science ®Google Scholar
• Yan SD, Chen X, Schmidt AM et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc. Natl Acad. Sci. USA91(16), 7787–7791 (1994).
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Bucala R, Suzuki T et al. Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J. Neuropathol. Exp. Neurol.59(12), 1094–1105 (2000).
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Hansen S, Karnes J et al. Capillary number and percentage closed in human diabetic sural nerve. Proc. Natl Acad. Sci. USA82(8), 2513–2517 (1985).
   PubMed Web of Science ®Google Scholar
• Huber JD. Diabetes, cognitive function, and the blood-brain barrier. Curr. Pharmaceut. Des.14(16), 1594–1600 (2008).
   PubMed Web of Science ®Google Scholar
• Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J. Mol. Med.82(8), 510–529 (2004).
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron57(2), 178–201 (2008).
   PubMed Web of Science ®Google Scholar
• Biessels GJ, De Leeuw FE, Lindeboom J, Barkhof F, Scheltens P. Increased cortical atrophy in patients with Alzheimer’s disease and Type 2 diabetes mellitus. J. Neurol. Neurosurg. Psychiatry77(3), 304–307 (2006).
   PubMed Web of Science ®Google Scholar
• Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer’s disease. Am. J. Alzheimers Dis. Other Demen.21(3), 197–208 (2006).
   PubMedGoogle Scholar
• Huber JD, VanGilder RL, Houser KA. Streptozotocin-induced diabetes progressively increases blood–brain barrier permeability in specific brain regions in rats. Am. J. Physiol.291(6), H2660–H2668 (2006).
   Google Scholar
• Banks WA, Jaspan JB, Kastin AJ. Effect of diabetes mellitus on the permeability of the blood–brain barrier to insulin. Peptides18(10), 1577–1584 (1997).
   PubMed Web of Science ®Google Scholar
• Seaquist ER, Tkac I, Damberg G, Thomas W, Gruetter R. Brain glucose concentrations in poorly controlled diabetes mellitus as measured by high-field magnetic resonance spectroscopy. Metabolism54(8), 1008–1013 (2005).
   PubMed Web of Science ®Google Scholar
• Clodfelder-Miller B, De Sarno P, Zmijewska AA, Song L, Jope RS. Physiological and pathological changes in glucose regulate brain Akt and glycogen synthase kinase-3. J. Biol. Chem.280(48), 39723–39731 (2005).
   PubMed Web of Science ®Google Scholar
• Girouard H, Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J. Appl. Physiol.100(1), 328–335 (2006).
   PubMed Web of Science ®Google Scholar
• Koehler RC, Gebremedhin D, Harder DR. Role of astrocytes in cerebrovascular regulation. J. Appl. Physiol.100(1), 307–317 (2006).
   PubMed Web of Science ®Google Scholar
• Rosengarten B, Huwendiek O, Kaps M. Neurovascular coupling and cerebral autoregulation can be described in terms of a control system. Ultrasound Med. Biol.27(2), 189–193 (2001).
   PubMed Web of Science ®Google Scholar
• Orozco LJ, Buchleitner AM, Gimenez-Perez G, Roque IFM, Richter B, Mauricio D. Exercise or exercise and diet for preventing Type 2 diabetes mellitus. Cochrane Database Syst. Rev. (3), CD003054 (2008).
   Google Scholar
• Taubes G. Good Calories, Bad Calories. AA Knopf, NY, USA (2008).
   Google Scholar
• Critser G. Fat Land: How Americans Became the Fattest People in the World. Houghton Mifflin Co., MA, USA (2004).
   Google Scholar
• Nielsen SJ, Siega-Riz AM, Popkin BM. Trends in energy intake in U.S. between 1977 and 1996: similar shifts seen across age groups. Obes. Res.10(5), 370–378 (2002).
   PubMedGoogle Scholar
• Bray GA, Nielsen SJ, Popkin BM. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am. J. Clin. Nutr.79(4), 537–543 (2004).
   PubMed Web of Science ®Google Scholar
• Wolf A, Bray GA, Popkin BM. A short history of beverages and how our body treats them. Obes. Rev.9, 151–164 (2007).
   Google Scholar
• Johnson RJ, Segal MS, Sautin Y et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am. J. Clin. Nutr.86(4), 899–906 (2007).
   PubMed Web of Science ®Google Scholar
• Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int. Rev. Neurobiol.50, 325–392 (2002).
   PubMed Web of Science ®Google Scholar
• Cassese A, Esposito I, Fiory F et al. In skeletal muscle advanced glycation end products (AGEs) inhibit insulin action and induce the formation of multimolecular complexes including the receptor for AGEs. J. Biol. Chem.283(52), 36088–36099 (2008).
   PubMed Web of Science ®Google Scholar
• Stirban A, Negrean M, Gotting C et al. Dietary advanced glycation endproducts and oxidative stress: in vivo effects on endothelial function and adipokines. Ann. NY Acad. Sci.1126, 276–279 (2008).
   PubMed Web of Science ®Google Scholar
• Tan D, Wang Y, Lo CY, Sang S, Ho CT. Methylglyoxal: its presence in beverages and potential scavengers. Ann. NY Acad. Sci.1126, 72–75 (2008).
   PubMed Web of Science ®Google Scholar
• Koschinsky T, He CJ, Mitsuhashi T et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc. Natl Acad. Sci. USA94(12), 6474–6479 (1997).
   PubMed Web of Science ®Google Scholar
• He C, Sabol J, Mitsuhashi T, Vlassara H. Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes48(6), 1308–1315 (1999).
   PubMed Web of Science ®Google Scholar
• Vlassara H. Advanced glycation in health and disease: role of the modern environment. Ann. NY Acad. Sci.1043, 452–460 (2005).
   PubMed Web of Science ®Google Scholar
• Hightower JM. Diagnosis: Mercury: Money, Politics, and Poison Island Press, London, UK (2008).
   Google Scholar
• Orgogozo JM, Dartigues JF, Lafont S et al. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev. Neurol. (Paris)153(3), 185–192 (1997).
   PubMed Web of Science ®Google Scholar
• Collins MA, Neafsey EJ, Mukamal KJ et al. Alcohol in moderation, cardioprotection, and neuroprotection: epidemiological considerations and mechanistic studies. Alcohol Clin. Exp. Res.33(2), 206–219 (2008).
   PubMed Web of Science ®Google Scholar
• Wang Z, Barker TH, Fuller GM. Alcohol at moderate levels decreases fibrinogen expression in vivo and in vitro. Alcohol Clin. Exp. Res.23(12), 1927–1932 (1999).
   PubMed Web of Science ®Google Scholar
• Wang J, Ho L, Qin W et al. Caloric restriction attenuates β-amyloid neuropathology in a mouse model of Alzheimer’s disease. FASEB J.19(6), 659–661 (2005).
   PubMed Web of Science ®Google Scholar
• Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci.21, 8370–8377 (2001).
   PubMed Web of Science ®Google Scholar
• Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J. Neurochem.102(4), 1095–1104 (2007).
   PubMed Web of Science ®Google Scholar
• Maher P, Akaishi T, Abe K. Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory. Proc. Natl Acad. Sci. USA103(44), 16568–16573 (2006).
   PubMed Web of Science ®Google Scholar
• Hu G, Lakka TA, Kilpelainen TO, Tuomilehto J. Epidemiological studies of exercise in diabetes prevention. Appl. Physiol. Nutr. Metab.32(3), 583–595 (2007).
   PubMed Web of Science ®Google Scholar
• Balogun E, Hoque M, Gong P et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem. J.371(Pt 3), 887–895 (2003).
   PubMed Web of Science ®Google Scholar
• Liu Y, Dargusch R, Maher P, Schubert D. A broadly neuroprotective derivative of curcumin. J. Neurochem.1051336–1345 (2008).
   PubMed Web of Science ®Google Scholar
• Maher P, Akaishi T, Schubert D, Abe K. A pyrazole derivative of curcumin enhances memory. Neurobiol. Aging (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Peyroux J, Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathol. Biol. (Paris)54(7), 405–419 (2006).
   PubMed Web of Science ®Google Scholar
• Wu CH, Yen GC. Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts. J. Agric. Food. Chem.53(8), 3167–3173 (2005).
   PubMed Web of Science ®Google Scholar
• Akaishi T, Morimoto T, Shibao M et al. Structural requirements for the flavonoid fisetin in inhibiting fibril formation of amyloid β protein. Neurosci. Lett.444(3), 280–285 (2008).
   PubMed Web of Science ®Google Scholar
• van Acker SA, van den Berg DJ, Tromp MN et al. Structural aspects of antioxidant activity of flavonoids. Free Radic. Biol. Med.20(3), 331–342 (1996).
   PubMed Web of Science ®Google Scholar
• Sagara Y, Vanhnasy J, Maher P. Induction of PC12 cell differentiation by flavonoids is dependent upon extracellular signal-regulated kinase activation. J. Neurochem.90(5), 1144–1155 (2004).
   PubMed Web of Science ®Google Scholar